SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:lup.lub.lu.se:be609918-8ce9-4a77-8674-5a5ec7564065"
 

Sökning: id:"swepub:oai:lup.lub.lu.se:be609918-8ce9-4a77-8674-5a5ec7564065" > Haploidentical Stem...

Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma

Illhardt, Toni (författare)
University Hospital of Tubingen
Toporski, Jacek (författare)
Skåne University Hospital
Feuchtinger, Tobias (författare)
German Center for Lung Research (DZL)
visa fler...
Turkiewicz, Dominik (författare)
Skåne University Hospital
Teltschik, Heiko Manuel (författare)
University Hospital of Tubingen
Ebinger, Martin (författare)
University Hospital of Tubingen
Schwarze, Carl Philipp (författare)
University Hospital of Tubingen
Holzer, Ursula (författare)
University Hospital of Tubingen
Lode, Holger N. (författare)
University Hospital Greifswald
Albert, Michael H. (författare)
German Center for Lung Research (DZL)
Gruhn, Bernd (författare)
Universitätsklinikum Jena
Urban, Christian (författare)
Medical University of Graz
Dykes, Josefina H. (författare)
Lund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine,Region Skåne
Teuffel, Oliver (författare)
University of Tübingen
Schumm, Michael (författare)
University Hospital of Tubingen
Handgretinger, Rupert (författare)
University Hospital of Tubingen
Lang, Peter (författare)
University Hospital of Tubingen
visa färre...
 (creator_code:org_t)
Elsevier BV, 2018
2018
Engelska.
Ingår i: Biology of Blood and Marrow Transplantation. - : Elsevier BV. - 1083-8791. ; 24:5, s. 1005-1012
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Pediatric patients with refractory or relapsed metastatic neuroblastoma (NBL) have a poor prognosis despite autologous stem cell transplantation (SCT). Allogeneic SCT from a haploidentical donor has a remarkable alloreactive effect in patients with leukemia; thus, we evaluated this approach in children with very high-risk NBL. We analyzed data from 2 prospective phase I/II trials. A total of 26 patients with refractory (n = 5), metastatic relapsed (n = 20), or locally relapsed MYCN-positive (n = 1) NBL received a median of 17 × 106/kg T/B cell-depleted CD34+ stem cells with 68 × 103/kg residual T cells and 107 × 106/kg natural killer cells. The conditioning regimen comprised melphalan, fludarabine, thiotepa, OKT3, and a short course of mycophenolate mofetil post-transplantation. Engraftment occurred in 96% of the patients. Event-free survival and overall survival at 5 years were 19% and 23%, respectively. No transplantation-related mortality was observed, and the single death was due to progression/subsequent relapse. The median duration of follow-up was 8.1 years. Patients in complete remission before SCT had a significantly better prognosis than those with residual tumor load (P < .01). All patients with progressive disease before SCT relapsed within 1 year. Grade II and grade III acute graft-versus-host disease (GVHD) occurred in 31% and 12% of the patients, respectively. Chronic limited and extensive GVHD occurred in 28% and 10%, respectively. Our data indicate that haploidentical SCT is a feasible treatment option that can induce long-term remission in some patients with NBL with tolerable side effects, and may enable the development of further post-transplantation therapeutic strategies based on the donor-derived immune system.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Hematologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Hematology (hsv//eng)

Nyckelord

Allogeneic stem cell transplantation
Graft-versus-host disease
Graft-versus-tumor effect
Haploidentical
Neuroblastoma
Transplantation-related mortality

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy